Repligen Corporation carries exceptional business quality with a perfect Piotroski F-Score of 9/9 and 134% free cash flow conversion, and analysts see 21% upside, but the stock trades at a forward P/E of 51.4x while sitting below its 200-day moving average with elevated bearish options positioning.
Thesis pillars
- Exceptional Financial Quality↓Deteriorating
- Earnings Beat Streak↓Deteriorating
- Valuation Premium Risk↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026· older than 90 days
Repligen Corporation (RGEN) Stock Analysis
Range Bound setup
Healthcare · Medical Instruments & Supplies
Sell if holding. Analyst target reached at $178.20 — A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single-source supplier (certain products).
Repligen develops and sells bioprocessing products across four franchises — Filtration, Chromatography, Process Analytics, and Proteins — used in manufacturing biological drugs including monoclonal antibodies, RNA therapeutics, and cell and gene therapies. Revenue comes... Read more
Sell if holding. Analyst target reached at $178.20 — A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single-source supplier (certain products). Chart setup: RSI 45 mid-range, Bollinger mid-band. Score 4.4/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 110d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
About Repligen Corporation
About Repligen Corporation
Repligen's bioprocessing portfolio spans four franchises — Filtration (the largest, including fluid management), Chromatography, Process Analytics, and Proteins — sold to biopharmaceutical companies, CDMOs, and diagnostics companies through a global commercial team of approximately 390 employees. North America accounted for 49% of 2025 revenue, Europe for 34%, and Asia Pacific and the rest of the world for 17%, with no single country outside the United States exceeding 10% of revenues. The company employs approximately 2,000 people and operates 19 manufacturing sites in the United States, Europe, and Asia.
Repligen generates the majority of revenue from consumable and single-use products — including TangenX TFF cassettes, hollow fiber filters, OPUS pre-packed chromatography columns, and process analytics instruments — that biopharmaceutical customers repurchase each manufacturing campaign. Hardware such as KrosFlo TFF systems and KRM chromatography systems complement the consumable base. For the Proteins franchise, the company holds a long-term supply agreement with Purolite extended through 2032 to supply affinity ligands for Protein A resins used in monoclonal antibody purification. Competitors include Danaher Corporation (Cytiva), Thermo Fisher Scientific, MilliporeSigma, and Sartorius, which may market products at lower prices given their greater scale. Supply for the XCell ATF cell retention systems relies on a small number of qualified material suppliers; transitioning to alternatives would require revalidation and could disrupt operations.
Show full overview
For certain products, Repligen relies on a single supplier, and the 10-K notes that transitioning to new suppliers would require altering operations, revalidating materials, and may involve interruptions in product availability. The XCell ATF franchise depends on a small pool of qualified material suppliers; if any qualified supplier exits or disrupts, revalidation requirements could delay product shipments. In December 2023, the company issued $600 million in 1.00% Convertible Senior Notes due 2028; the ability to service this obligation depends on continued cash generation from bioprocessing product sales, subject to economic, financial, and competitive factors.
See also: Healthcare · Medical Instruments & Supplies
From Repligen Corporation's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated Oct 28, 2026Recent Developments — Repligen Corporation
Latest news
- NEWS Repligen (RGEN) Could Be 12% Undervalued As Record Revenue Lifts Guidance - Yahoo Finance — Yahoo Finance Oct 28, 2026 positive
- NEWS Repligen (RGEN) Stock Faces Q3 Earnings Margin Squeeze - Simply Wall Street — Simply Wall Street Oct 27, 2026 negative
- NEWS Repligen (RGEN) Takes $41.2 Million Impairment Charge As Quarterly Profit Turns To Loss - Yahoo Finance — Yahoo Finance Oct 27, 2026 negative
- NEWS Repligen (RGEN) Stock Looks Reasonably Priced As Cash Flow Expectations Settle - Simply Wall Street — Simply Wall Street Oct 27, 2026 neutral
- NEWS Repligen Corp (RGEN) Shares Surge 11.0% -- What GF Score of 87 T - GuruFocus — GuruFocus Jul 29, 2026 positive
Latest item Oct 28, 2026 · Generated 2026-11-05T12:04:09Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicNorth America49%10-K Item 1: 'North America ... 49'
- HIGHSuppliersingle-source supplier (certain products)10-K Item 1A: 'We rely on a limited number of suppliers or, for certain of our products, one supplier'
- MEDIUMSupplierXCell ATF material suppliers10-K Item 1A: 'only a small number of suppliers are currently qualified to supply materials for the XCell ATF® systems'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $178.20 — A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single-source supplier (certain products). Chart setup: RSI 45 mid-range, Bollinger mid-band. Prior stop was $165.73. Score 4.4/10, moderate confidence.
Analyst target: $183.10 (+2.8% upside). Prior stop was $165.73. Stop-loss: $165.73.
Concentration risk — Supplier: single-source supplier (certain products); Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2).
Repligen Corporation trades at a P/E of N/A (forward 67.1). TrendMatrix value score: 2.5/10. Verdict: Sell.
27 analysts rate RGEN, with a consensus score of 4.1/5. 20 analysts publish price targets averaging $203.
What does Repligen Corporation do?Repligen develops and sells bioprocessing products across four franchises — Filtration, Chromatography, Process...
Repligen develops and sells bioprocessing products across four franchises — Filtration, Chromatography, Process Analytics, and Proteins — used in manufacturing biological drugs including monoclonal antibodies, RNA therapeutics, and cell and gene therapies. Revenue comes predominantly from consumable and single-use product sales to biopharmaceutical companies and CDMOs, with approximately 2,000 employees and 19 manufacturing sites globally. North America represented 49% of 2025 revenue.